TPG-backed Pathology Asia invests Australia's Safe Work
TPG Capital Asia’s Pathology Asia platform has continued a regional roll-up strategy with an investment of undisclosed size in a minority stake in Australian drug testing specialist Safe Work Laboratories.
It follows the acquisition in July last year of a portfolio of 39 pathology laboratories across Singapore, Malaysia, and Vietnam from Australian hospital operator Healthscope for A$279 million ($200 million)....
More on Australasia
Latest News
Exit strategy: Good timing
KKR helps make the argument for realizing early exits when it supports a fundraising process, but LP reactions to this approach remain a mix of approval, suspicion and resignation
New Horizon buys Japan cosmetics player from Ant Capital
Japanese private equity firm New Horizon Capital has acquired 100% of Kagayaku Cosmetics from Ant Capital Partners for an undisclosed sum.
SoftBank Ventures Asia hits $269m first close on global fund
SoftBank Ventures Asia – previously known as SoftBank Ventures Korea – has reached a first close of KRW317.4 billion ($269 million) on a fund that will make early-stage investments globally with a focus on Asia.
Brookfield to lead $3.7b investment in Reliance India telecom unit
A consortium led by Brookfield Asset Management has agreed to invest INR252 billion ($3.66 billion) in the telecommunication tower unit of India’s Reliance Industries. It is said to be the largest foreign investment in an Indian infrastructure asset...